retatrutide clinical studies retatrutide for Sale in the US Eli Lilly infiltrates anti-obesity market

Hostetler More than 85% of obese participants with fatty liver disease in a clinical trial of the experimental drug retatrutide reduced their liver fat to the point where they would no longer be classified as having fatty liver disease, according to the Virginia Commonwealth University hepatologist leading the sub-study

Edwin Davila, an osteopathic physician and member of NASM's Scientific Advisory Board

This product is not supplied for human, veterinary, therapeutic, cosmetic or personal use

Burner TW, Rosenthal AK

Clin Gastroenterol Hepatol 2023;21:2876-2888 e5

Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes